NC-LENOVO
28.8.2024 15:01:27 CEST | Business Wire | Press release
Lenovo (HKSE: 992) (ADR: LNVGY), the global technology powerhouse, is offering Lenovo Hybrid Cloud Advisory Services to help enterprises simplify the complexity of hybrid cloud design and create implementation-ready, future-proofed plans in as few as six weeks. Lenovo leverages four decades of experience helping global CIOs ease cloud and hybrid cloud challenges, including demands associated with emerging AI-related workloads. With the new services, Lenovo expert consultants guide enterprises through hybrid cloud needs, accelerating time to value, improving cost efficiency, and building flexibly scalable foundations.
The new era of AI is hybrid, and today’s IT organizations are converting their raw data into actionable insights with hybrid cloud solutions that are capable of harnessing data, no matter where it lives. Lenovo hybrid cloud solutions boost AI performance and agility by delivering more compute and faster memory when and where it’s needed, offering a full-stack portfolio and purpose-built solutions that are specific to each customer and use case. To support AI optimization, Lenovo Hybrid Cloud Advisory Services help design a cloud approach customized for today, and ready to flexibly scale and adapt to future needs.
“At a time when the need for modern infrastructure and solutions has never been greater, IT is challenged to evolve cloud implementations. This is evident in our most recent Lenovo global CIO report in which 82% of respondents marked cloud transformation as challenging,” said Dale Aultman, Vice President & General Manager, Hybrid Cloud Services at Lenovo Group. “We introduced Lenovo Hybrid Cloud Advisory Services to simplify cloud design strategies and pave the way for AI implementations. We bring a global team of trusted experts to help our customers develop future-proofed, tailor-made solutions to rapidly modernize hybrid clouds and ultimately deliver better business outcomes.”
Many organizations need to modernize or update their hybrid clouds due to changing business needs, spiraling costs, or performance issues. In fact, Lenovo’s third annual global CIO report found that 29% of respondents still find cloud transformation a top priority, behind AI implementation, cybersecurity, and data privacy. Demand for data center capacity continues to grow and, with increasing interest in AI, is also accelerating. IT leaders are concerned about meeting this demand due to challenges around qualified staff, procuring equipment, forecasting future requirements and energy efficiencies. Changing licensing models are also generating disruption and requiring IT leaders to lean on partners.
“Successful hybrid cloud strategy and design is imperative for enterprises, yet the underlying complexity involved cannot be understated,” said Steven Dickens, Futurum Group. “According to our research, hybrid is 2x the size of public cloud when it comes to deployment modalities for AI, therefore the need for flexibility and futureproofing becomes critical. Partnering with experts, such as Lenovo, will be the smart path forward for many enterprises.”
Lenovo Hybrid Cloud Advisory Services offers customized, strategic expertise, and a trusted partner to manage the complexity of hybrid cloud design. Lenovo experts help turn hybrid cloud vision into reality with better outcomes using customer assessment, proven methodologies, and strategic advice and approach recommendation. Lenovo’s tech-agnostic expertise, deep industry alliances and partnerships, pre-validated solutions, and experience in every aspect of hybrid cloud creation provide clear value while helping future-proof an organization’s hybrid cloud. Customer benefits include:
- Speed/Time to value
- Holistic: Cloud/software/infrastructure expertise from single provider
- End-to-end expertise
- Engineering quality
- Global presence
Lenovo Hybrid Cloud Advisory Services features a breadth of offerings that are now available, expanding Lenovo’s advisory services capabilities and complementing Lenovo’s AI services portfolio. Channel availability will launch in September 2024.
For more information regarding Lenovo Hybrid Cloud Advisory Services visit here.
About Lenovo
Lenovo is a US$57 billion revenue global technology powerhouse, ranked #248 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (data center, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828812342/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom